PL2308885T3 - Nowe związki i sposoby leczenia - Google Patents

Nowe związki i sposoby leczenia

Info

Publication number
PL2308885T3
PL2308885T3 PL11151008T PL11151008T PL2308885T3 PL 2308885 T3 PL2308885 T3 PL 2308885T3 PL 11151008 T PL11151008 T PL 11151008T PL 11151008 T PL11151008 T PL 11151008T PL 2308885 T3 PL2308885 T3 PL 2308885T3
Authority
PL
Poland
Prior art keywords
therapy
methods
novel compounds
novel
compounds
Prior art date
Application number
PL11151008T
Other languages
English (en)
Inventor
Gabriel Birkus
Adrian S Ray
Daniel Tumas
William J Watkins
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2308885T3 publication Critical patent/PL2308885T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plasma & Fusion (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11151008T 2008-02-20 2009-02-19 Nowe związki i sposoby leczenia PL2308885T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3014808P 2008-02-20 2008-02-20
EP11151008.7A EP2308885B1 (en) 2008-02-20 2009-02-19 Novel compounds and methods for therapy
EP09712645.2A EP2245037B1 (en) 2008-02-20 2009-02-19 Novel compounds and methods for therapy

Publications (1)

Publication Number Publication Date
PL2308885T3 true PL2308885T3 (pl) 2015-04-30

Family

ID=40532651

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09712645T PL2245037T4 (pl) 2008-02-20 2009-02-19 Nowe związki i sposoby leczenia
PL11151008T PL2308885T3 (pl) 2008-02-20 2009-02-19 Nowe związki i sposoby leczenia

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09712645T PL2245037T4 (pl) 2008-02-20 2009-02-19 Nowe związki i sposoby leczenia

Country Status (18)

Country Link
US (1) US8163718B2 (pl)
EP (2) EP2308885B1 (pl)
JP (2) JP5588356B2 (pl)
KR (2) KR101612138B1 (pl)
CN (2) CN105753905A (pl)
AR (1) AR071159A1 (pl)
AU (3) AU2009215547B2 (pl)
CA (1) CA2715885C (pl)
CY (2) CY1115571T1 (pl)
DK (2) DK2308885T3 (pl)
ES (2) ES2516715T3 (pl)
HR (2) HRP20140895T1 (pl)
NZ (1) NZ587464A (pl)
PL (2) PL2245037T4 (pl)
PT (2) PT2308885E (pl)
SI (2) SI2245037T1 (pl)
TW (1) TWI444384B (pl)
WO (1) WO2009105513A2 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
CN103690928B (zh) 2009-01-08 2016-04-20 株式会社癌免疫研究所 新型癌抗原eEF2
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CN102093422B (zh) * 2009-12-10 2015-02-25 中国人民解放军军事医学科学院毒物药物研究所 无环核苷膦酸酯衍生物及其医药用途
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CN107312039B (zh) * 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2014077784A1 (en) * 2012-11-19 2014-05-22 Agency For Science, Technology And Research Method of treating cancer
SG11201502796RA (en) * 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017027434A1 (en) * 2015-08-10 2017-02-16 Merck Sharp & Dohme Corp. Antiviral beta-amino acid ester phosphodiamide compounds
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
WO2017100108A1 (en) * 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US11236093B2 (en) * 2016-05-04 2022-02-01 B.C.I. Pharma Adenine derivatives as protein kinase inhibitors
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
KR20190100250A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 테노포비르의 항바이러스 지방족 에스테르 전구약물
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
EP3823629B1 (en) 2018-07-19 2024-12-25 Merck Sharp & Dohme LLC Phosphinic amide prodrugs of tenofovir
CN112778363B (zh) * 2019-11-05 2024-03-15 华创合成制药股份有限公司 一种硝基咪唑类唑衍生物及其制备方法和用途
KR20250052378A (ko) * 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617457A1 (de) * 1966-12-16 1972-04-20 Erba Carlo Spa Verfahren zur Stabilisierung von Zubereitungen interferierender Virusprodukte
US3665838A (en) * 1970-01-29 1972-05-30 Wilson Lighting Ltd Air chamber assembly
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
US4740365A (en) 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
US5141752A (en) 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
IL84477A (en) 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
US5459256A (en) 1987-04-17 1995-10-17 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Lipophilic, aminohydrolase-activated prodrugs
GB8802142D0 (en) * 1988-02-01 1988-03-02 Air Prod & Chem Method of freezing liquid & pasty products & freezer for carrying out said method
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
PT95516A (pt) 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
CZ285420B6 (cs) 1990-04-24 1999-08-11 Ústav Organické Chemie A Biochemie Avčr N-(3-Fluor-2-fosfonylmethoxypropyl)deriváty purinových a pyrimidinových heterocyklických bazí, způsoby jejich přípravy a použití
JPH05509307A (ja) 1990-07-19 1993-12-22 ビーチャム・グループ・パブリック・リミテッド・カンパニー プリンの抗ウイルス性ホスホノ―アルケン誘導体
EP0468119A1 (en) 1990-07-24 1992-01-29 Merrell Dow Pharmaceuticals Inc. Novel carbocyclic analogs of certain nucleosides
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
EP0630381B1 (en) 1991-10-11 1997-04-09 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
DE69426904T2 (de) * 1993-06-29 2001-10-11 Mitsubishi Chemical Corp., Tokio/Tokyo Phosphonat-Nukleotid Ester-Derivate
ATE486882T1 (de) 1993-09-17 2010-11-15 Gilead Sciences Inc Nukleotidanaloge
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
IL120202A (en) * 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
FR2862306B1 (fr) * 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
US7553825B2 (en) 2003-12-30 2009-06-30 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
ATE542095T1 (de) * 2004-07-23 2012-02-15 Bayer Technology Services Gmbh Verfahren zum sterilen gefrieren, trocknen, lagern, analysieren und füllen (sfd-saf- verfahren) (verfahren zur gefriertrocknung von granulat für parenterale biopharmazeutika)
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
WO2007002808A1 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof
ATE534377T1 (de) 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
US9521854B2 (en) * 2006-05-31 2016-12-20 Air Liquide Industrial U.S. Lp Method and device for creating frozen pellets of a foodstuff
US8338593B2 (en) * 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CN101066981B (zh) * 2007-05-25 2011-10-05 中国科学院上海药物研究所 非环核苷膦酸酯类化合物及其组合物、制备方法和用途

Also Published As

Publication number Publication date
AU2016250468A1 (en) 2016-11-17
KR101612138B1 (ko) 2016-04-12
DK2308885T3 (da) 2015-02-23
EP2308885A3 (en) 2011-05-11
ES2516715T3 (es) 2014-10-31
EP2308885A2 (en) 2011-04-13
EP2308885B1 (en) 2014-11-19
EP2245037B1 (en) 2014-06-18
CN105753905A (zh) 2016-07-13
DK2245037T3 (da) 2014-09-29
WO2009105513A3 (en) 2009-11-12
WO2009105513A8 (en) 2009-11-12
AU2014203786A1 (en) 2014-07-31
CY1115571T1 (el) 2017-01-04
HK1150313A1 (en) 2011-11-25
CN102015739B (zh) 2016-03-09
WO2009105513A2 (en) 2009-08-27
ES2529209T3 (es) 2015-02-18
AR071159A1 (es) 2010-06-02
CA2715885A1 (en) 2009-08-27
PT2308885E (pt) 2015-02-10
TWI444384B (zh) 2014-07-11
JP2014088416A (ja) 2014-05-15
NZ587464A (en) 2012-07-27
CY1116015T1 (el) 2017-01-25
JP2011514336A (ja) 2011-05-06
SI2245037T1 (sl) 2014-12-31
US20090232768A1 (en) 2009-09-17
KR20160041061A (ko) 2016-04-15
TW200948823A (en) 2009-12-01
CN102015739A (zh) 2011-04-13
HK1156631A1 (en) 2012-06-15
CA2715885C (en) 2016-06-28
KR20100127242A (ko) 2010-12-03
AU2009215547A1 (en) 2009-08-27
HRP20140895T1 (hr) 2014-12-19
SI2308885T1 (sl) 2015-03-31
AU2009215547B2 (en) 2014-04-10
AU2014203786B2 (en) 2016-11-17
PT2245037E (pt) 2014-10-24
PL2245037T4 (pl) 2015-06-30
PL2245037T3 (pl) 2015-01-30
US8163718B2 (en) 2012-04-24
HRP20150005T1 (hr) 2015-04-24
KR101728647B1 (ko) 2017-04-19
EP2245037A2 (en) 2010-11-03
JP5588356B2 (ja) 2014-09-10

Similar Documents

Publication Publication Date Title
SI2245037T1 (sl) Nove spojine in postopki za zdravljenje
IL206654A0 (en) Combination therapy
GB0823213D0 (en) Treatment
GB0813740D0 (en) Therapeutic compounds
GB0802116D0 (en) Treatment
GB0808973D0 (en) Radiotherapy apparatus
GB0806794D0 (en) Therapeutic compounds
GB0822011D0 (en) Treatment
GB0804755D0 (en) Therapeutic compounds
GB0819280D0 (en) Imgaing and radiotherapy methods
GB0803477D0 (en) Therapy selection method
HUE038611T2 (hu) Vitiligo terápia
GB0815788D0 (en) Therapeutic antibodies
GB0811992D0 (en) Treatment
EP2324059A4 (en) THERAPEUTIC ANTI-PAMP ANTIBODIES
GB201008346D0 (en) Methods and compounds for phototransfer
GB0803948D0 (en) Combination therapy
GB0820972D0 (en) Treatment
GB0722274D0 (en) New therapeutic method
GB0805912D0 (en) Treatment
GB0813292D0 (en) Therapy
GB0812659D0 (en) Therapy
GB0814479D0 (en) Therapeutic method
GB0819645D0 (en) New therapy
GB0819642D0 (en) New therapy